4:53 PM
 | 
Sep 21, 2017
 |  BC Extra  |  Clinical News

Akari gains on Phase III PNH plans for C5 inhibitor

Akari Therapeutics plc (NASDAQ:AKTX) gained $3.15 (56%) to $8.74 on Thursday after the company announced plans to start Phase III testing in 1Q18 of lead candidate Coversin to treat paroxysmal nocturnal hemoglobinuria.

The announcement appears to have removed an overhang that has weighed on Akari shares since spring, when Edison Investment Research Ltd. retracted a report titled “Akari’s Coversin matches Soliris in...

Read the full 297 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >